GLA
XLRN

Great Lakes Advisors’s Acceleron Pharma XLRN Stock Holding History

Great Lakes Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-136,480
Closed -$7.24M – 603
2019
Q4 		$7.24M Buy
+136,480
New +$6.22M 0.16% 169

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Great Lakes Advisors's XLRN Position: Q1 2020 in Review

Great Lakes Advisors sold out of Acceleron Pharma (XLRN) in Q1 2020, closing a stake of 136,480 shares — an estimated $7.24M sold.

Great Lakes Advisors first reported a position in XLRN in Q4 2019 and held it in 1 quarter. The position peaked at $7.24M in Q4 2019. 217 funds tracked by Wall St. Rank hold XLRN as of Q1 2020.

  • Great Lakes Advisors reported no remaining Acceleron Pharma position as of Q1 2020 after selling out during the quarter.
  • Great Lakes Advisors sold 136,480 Acceleron Pharma shares in Q1 2020, an estimated $7.24M.
  • Great Lakes Advisors first reported a position in Acceleron Pharma in Q4 2019 and held it in 1 quarter.
  • Great Lakes Advisors's Acceleron Pharma position peaked at $7.24M in Q4 2019.
  • 217 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2020.

Based on Great Lakes Advisors's 13F filing for Q1 2020, filed 8 May 2020.